FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220761738> ?p ?o ?g. }

• W4220761738 endingPage "1919" @default.
• W4220761738 startingPage "1914" @default.
• W4220761738 abstract "Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have been used to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulness of the new cardiovascular risk assessment model proposed by the Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the ESC in collaboration with the International Cardio-Oncology Society (ICOS) to stratify the cardiovascular risk in CML patients, compared with SCORE risk charts. The secondary aim was to establish the incidence of adverse arterial events (AEs) in patients with CML treated with TKIs and the influence of preventive treatment with aspirin.A retrospective single-centre observational study was carried out on 58 patients (32 men and 26 women; mean age ± SD: 59 ± 15 years) with CML treated with TKIs for a median period of 43 ± 31 months. Cardiological evaluation was performed and cardiovascular risk was estimated with SCORE risk charts and with the new risk assessment tool proposed by HFA/ICOS. AEs were recorded. According to SCORE charts and the new HFA/ICOS risk stratification tool, respectively, 46% (Group A1) and 60% (Group A2) of patients were at high-very high risk, and 54% (Group B1) and 40% (Group B2) at low-moderate risk. AEs were significantly more frequent in Group A1 than Group B1 (P value < 0.01) when considered overall; they were significantly more frequent in Group A2 than Group B2 either overall or considered individually. HFA/ICOS risk stratification tool was significantly more sensitive than SCORE (P < 0.01) in identifying patients at higher risk of cardiovascular toxicity. In addition, we did not find AEs in patients pretreated with aspirin.The new HFA/ICOS risk stratification model allows a more tailored cardiovascular risk stratification in patients with CML and it is more sensitive than SCORE charts." @default.
• W4220761738 created "2022-04-03" @default.
• W4220761738 creator A5012653604 @default.
• W4220761738 creator A5014426314 @default.
• W4220761738 creator A5017141261 @default.
• W4220761738 creator A5054138147 @default.
• W4220761738 creator A5057329904 @default.
• W4220761738 creator A5059792968 @default.
• W4220761738 creator A5085841362 @default.
• W4220761738 date "2022-03-31" @default.
• W4220761738 modified "2023-09-27" @default.
• W4220761738 title "The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity" @default.
• W4220761738 cites W1880435494 @default.
• W4220761738 cites W2107165713 @default.
• W4220761738 cites W2120665581 @default.
• W4220761738 cites W2124624517 @default.
• W4220761738 cites W2199506938 @default.
• W4220761738 cites W2402599050 @default.
• W4220761738 cites W2471327176 @default.
• W4220761738 cites W2473480037 @default.
• W4220761738 cites W2526416288 @default.
• W4220761738 cites W2735666722 @default.
• W4220761738 cites W2790692615 @default.
• W4220761738 cites W2800361199 @default.
• W4220761738 cites W2916784537 @default.
• W4220761738 cites W2924353663 @default.
• W4220761738 cites W3004564242 @default.
• W4220761738 cites W3011371150 @default.
• W4220761738 cites W3019434263 @default.
• W4220761738 cites W3021842026 @default.
• W4220761738 cites W3031292493 @default.
• W4220761738 cites W3118881001 @default.
• W4220761738 cites W3162195278 @default.
• W4220761738 cites W3197233987 @default.
• W4220761738 cites W3215337877 @default.
• W4220761738 cites W4220761738 @default.
• W4220761738 doi "https://doi.org/10.1002/ehf2.13897" @default.
• W4220761738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35355425" @default.
• W4220761738 hasPublicationYear "2022" @default.
• W4220761738 type Work @default.
• W4220761738 citedByCount "6" @default.
• W4220761738 countsByYear W42207617382022 @default.
• W4220761738 countsByYear W42207617382023 @default.
• W4220761738 crossrefType "journal-article" @default.
• W4220761738 hasAuthorship W4220761738A5012653604 @default.
• W4220761738 hasAuthorship W4220761738A5014426314 @default.
• W4220761738 hasAuthorship W4220761738A5017141261 @default.
• W4220761738 hasAuthorship W4220761738A5054138147 @default.
• W4220761738 hasAuthorship W4220761738A5057329904 @default.
• W4220761738 hasAuthorship W4220761738A5059792968 @default.
• W4220761738 hasAuthorship W4220761738A5085841362 @default.
• W4220761738 hasBestOaLocation W42207617381 @default.
• W4220761738 hasConcept C11783203 @default.
• W4220761738 hasConcept C120665830 @default.
• W4220761738 hasConcept C121332964 @default.
• W4220761738 hasConcept C12174686 @default.
• W4220761738 hasConcept C126322002 @default.
• W4220761738 hasConcept C197934379 @default.
• W4220761738 hasConcept C23131810 @default.
• W4220761738 hasConcept C2776694085 @default.
• W4220761738 hasConcept C2778198053 @default.
• W4220761738 hasConcept C2778233292 @default.
• W4220761738 hasConcept C2779134260 @default.
• W4220761738 hasConcept C38652104 @default.
• W4220761738 hasConcept C41008148 @default.
• W4220761738 hasConcept C61511704 @default.
• W4220761738 hasConcept C71924100 @default.
• W4220761738 hasConceptScore W4220761738C11783203 @default.
• W4220761738 hasConceptScore W4220761738C120665830 @default.
• W4220761738 hasConceptScore W4220761738C121332964 @default.
• W4220761738 hasConceptScore W4220761738C12174686 @default.
• W4220761738 hasConceptScore W4220761738C126322002 @default.
• W4220761738 hasConceptScore W4220761738C197934379 @default.
• W4220761738 hasConceptScore W4220761738C23131810 @default.
• W4220761738 hasConceptScore W4220761738C2776694085 @default.
• W4220761738 hasConceptScore W4220761738C2778198053 @default.
• W4220761738 hasConceptScore W4220761738C2778233292 @default.
• W4220761738 hasConceptScore W4220761738C2779134260 @default.
• W4220761738 hasConceptScore W4220761738C38652104 @default.
• W4220761738 hasConceptScore W4220761738C41008148 @default.
• W4220761738 hasConceptScore W4220761738C61511704 @default.
• W4220761738 hasConceptScore W4220761738C71924100 @default.
• W4220761738 hasIssue "3" @default.
• W4220761738 hasLocation W42207617381 @default.
• W4220761738 hasLocation W42207617382 @default.
• W4220761738 hasLocation W42207617383 @default.
• W4220761738 hasLocation W42207617384 @default.
• W4220761738 hasOpenAccess W4220761738 @default.
• W4220761738 hasPrimaryLocation W42207617381 @default.
• W4220761738 hasRelatedWork W1430575998 @default.
• W4220761738 hasRelatedWork W1970383787 @default.
• W4220761738 hasRelatedWork W1998556240 @default.
• W4220761738 hasRelatedWork W2275480158 @default.
• W4220761738 hasRelatedWork W2313076522 @default.
• W4220761738 hasRelatedWork W2998970160 @default.
• W4220761738 hasRelatedWork W4237806278 @default.
• W4220761738 hasRelatedWork W4247718175 @default.
• W4220761738 hasRelatedWork W4254405463 @default.

• next